{"transactions":[{"id":1427283,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:08:58.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":23191,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024."}],"balance_after":23191,"derivative":{"exercise_price":3.56,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":23191},"source":{"system":"sec-edgar","filing":"0000950170-24-099303","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":10,"url":"https://www.sec.gov/Archives/edgar/data/1678223/000095017024099303/ownership.xml","form_type":"4"}},{"id":1427282,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:08:58.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":36852,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024."}],"balance_after":36852,"derivative":{"exercise_price":3.56,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":36852},"source":{"system":"sec-edgar","filing":"0000950170-24-099303","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1678223/000095017024099303/ownership.xml","form_type":"4"}},{"id":1427281,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:08:58.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":54871,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023."}],"balance_after":54871,"derivative":{"exercise_price":3.56,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":54871},"source":{"system":"sec-edgar","filing":"0000950170-24-099303","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1678223/000095017024099303/ownership.xml","form_type":"4"}},{"id":1427280,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:08:58.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":19948,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 48 substantially equal monthly installments beginning on January 6, 2022."}],"balance_after":19948,"derivative":{"exercise_price":3.56,"expiration_date":"2031-12-05","underlying":"Common Stock","underlying_shares":19948},"source":{"system":"sec-edgar","filing":"0000950170-24-099303","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1678223/000095017024099303/ownership.xml","form_type":"4"}},{"id":1427279,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:08:58.000Z","date":"2024-08-19","kind":"grant","planned":false,"acquired":true,"shares":82051,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F7","text":"The exercise price of the option is $3.56 per share, representing the fair market value per share of the common stock on the date of the repricing; provided that the exercise price will be increased to the original exercise price before repricing if, prior to the \"premium end date\" (as defined below), the repriced option is exercised or the reporting person's employment is terminated for any reason other than a \"qualifying termination\" (as defined below). The \"premium end date\" means the earliest of: (i) August 19, 2026, (ii) the date immediately prior to the closing of a change in control, or (iii) the date of the employee's qualifying termination. A \"qualifying termination\" means (a) the involuntary termination of the employee's employment by the Company due to a reduction in force (and other than for cause), or (b) the employee's termination due to death or disability."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vested as to 25% of the underlying shares on August 9, 2022, and vests as to the remaining underlying shares in 36 substantially equal monthly installments thereafter."}],"balance_after":82051,"derivative":{"exercise_price":3.56,"expiration_date":"2031-09-14","underlying":"Common Stock","underlying_shares":82051},"source":{"system":"sec-edgar","filing":"0000950170-24-099303","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1678223/000095017024099303/ownership.xml","form_type":"4"}},{"id":1427278,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:08:58.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":23191,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F6","text":"The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024."}],"balance_after":0,"derivative":{"exercise_price":16,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":23191},"source":{"system":"sec-edgar","filing":"0000950170-24-099303","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1678223/000095017024099303/ownership.xml","form_type":"4"}},{"id":1427277,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:08:58.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":36852,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The stock option vests in 48 substantially equal monthly installments beginning on March 15, 2024."}],"balance_after":0,"derivative":{"exercise_price":8.19,"expiration_date":"2034-02-14","underlying":"Common Stock","underlying_shares":36852},"source":{"system":"sec-edgar","filing":"0000950170-24-099303","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1678223/000095017024099303/ownership.xml","form_type":"4"}},{"id":1427276,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:08:58.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":54871,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The stock option vests in 48 substantially equal monthly installments beginning on July 13, 2023."}],"balance_after":0,"derivative":{"exercise_price":4.1,"expiration_date":"2033-06-12","underlying":"Common Stock","underlying_shares":54871},"source":{"system":"sec-edgar","filing":"0000950170-24-099303","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1678223/000095017024099303/ownership.xml","form_type":"4"}},{"id":1427275,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:08:58.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":19948,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The stock option vests in 48 substantially equal monthly installments beginning on January 6, 2022."}],"balance_after":0,"derivative":{"exercise_price":4.1,"expiration_date":"2031-12-05","underlying":"Common Stock","underlying_shares":19948},"source":{"system":"sec-edgar","filing":"0000950170-24-099303","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1678223/000095017024099303/ownership.xml","form_type":"4"}},{"id":1427274,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option","published_at":"2024-08-20T19:08:58.000Z","date":"2024-08-19","kind":"disposition_to_issuer","planned":false,"acquired":false,"shares":82051,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On August 19, 2024, the Issuer repriced the option. Except as described further in footnote 7, all other terms of the option remain unchanged."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vested as to 25% of the underlying shares on August 9, 2022, and vests as to the remaining underlying shares in 36 substantially equal monthly installments thereafter."}],"balance_after":0,"derivative":{"exercise_price":4.1,"expiration_date":"2031-09-14","underlying":"Common Stock","underlying_shares":82051},"source":{"system":"sec-edgar","filing":"0000950170-24-099303","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678223/000095017024099303/ownership.xml","form_type":"4"}},{"id":1557398,"issuer":{"id":7063,"kind":"organization","name":"Boundless Bio, Inc."},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Stock Option","published_at":"2024-03-29T16:30:16.000Z","date":"2024-03-27","kind":"grant","planned":false,"acquired":true,"shares":23191,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The stock option vests in 48 substantially equal monthly installments beginning on April 27, 2024."}],"balance_after":23191,"derivative":{"exercise_price":16,"expiration_date":"2034-03-26","underlying":"Common Stock","underlying_shares":23191},"source":{"system":"sec-edgar","filing":"0000950170-24-038695","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1678223/000095017024038695/ownership.xml","form_type":"4"}},{"id":2756715,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-04-05T18:24:31.000Z","date":"2021-04-01","kind":"sale","acquired":false,"shares":1469,"price":2.66,"value":3907.54,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of PRSUs on 03/31/21. These sales are mandated by the Reporting Person's election to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."}],"balance_after":57471,"source":{"system":"sec-edgar","filing":"0001610618-21-000032","document":"wf-form4_161766135780282.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000161061821000032/wf-form4_161766135780282.xml","form_type":"4"}},{"id":2756714,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-04-05T18:24:31.000Z","date":"2021-03-31","kind":"grant","acquired":true,"shares":3500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F2","text":"The reporting person was previously granted a performance restricted stock unit (PRSU) to vest upon the achievement of a certain milestone event that occurred on 3/31/21."}],"balance_after":58940,"source":{"system":"sec-edgar","filing":"0001610618-21-000032","document":"wf-form4_161766135780282.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000161061821000032/wf-form4_161766135780282.xml","form_type":"4"}},{"id":2756713,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2021-04-05T18:24:31.000Z","date":"2021-01-05","kind":"sale","acquired":false,"shares":2868,"price":2.06,"value":5908.08,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on 1/1/21. These sales are mandated by the Reporting Person's election to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."}],"balance_after":55440,"source":{"system":"sec-edgar","filing":"0001610618-21-000032","document":"wf-form4_161766135780282.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000161061821000032/wf-form4_161766135780282.xml","form_type":"4"}},{"id":2777203,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2021-03-19T21:04:48.000Z","date":"2021-03-17","kind":"grant","acquired":true,"shares":150000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 17, 2021."}],"balance_after":150000,"derivative":{"exercise_price":2.55,"expiration_date":"2031-03-16","underlying":"Common Stock","underlying_shares":150000},"source":{"system":"sec-edgar","filing":"0001610618-21-000022","document":"wf-form4_161620227196498.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000161061821000022/wf-form4_161620227196498.xml","form_type":"4"}},{"id":3099535,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-06-25T20:03:23.000Z","date":"2020-01-03","kind":"sale","acquired":false,"shares":940,"price":3.42,"value":3214.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This amendment is being filed to correct the number of shares sold which were underreported by 940 shares (i.e. a total of 3,280 shares were sold rather than 2,340) and to correct the end of period holdings to reduce such amount by 940 shares."},{"field":"shares","element":"transactionShares","label":"F2","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on 12/31/19. These sales are mandated by the Reporting Person's election to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"This amendment is being filed to correct the number of shares sold which were underreported by 940 shares (i.e. a total of 3,280 shares were sold rather than 2,340) and to correct the end of period holdings to reduce such amount by 940 shares."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F3","text":"Includes 4,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on November 20, 2019."}],"balance_after":50308,"source":{"system":"sec-edgar","filing":"0001209191-20-039025","document":"doc4a.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919120039025/doc4a.xml","form_type":"4/A","original_submission_date":"2020-01-06"}},{"id":3197600,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2020-03-23T19:33:35.000Z","date":"2020-03-19","kind":"grant","acquired":true,"shares":115000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 19, 2020."}],"balance_after":115000,"derivative":{"exercise_price":1.98,"expiration_date":"2030-03-18","underlying":"Common Stock","underlying_shares":115000},"source":{"system":"sec-edgar","filing":"0001209191-20-020756","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919120020756/doc4.xml","form_type":"4"}},{"id":3317434,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2020-01-06T17:27:49.000Z","date":"2020-01-03","kind":"sale","acquired":false,"shares":2340,"price":3.42,"value":8002.8,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on 12/31/19. These sales are mandated by the Reporting Person's election to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on November 20, 2019."}],"balance_after":51248,"source":{"system":"sec-edgar","filing":"0001209191-20-002034","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919120002034/doc4.xml","form_type":"4"}},{"id":3333729,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-12-20T16:36:48.000Z","date":"2019-12-18","kind":"grant","acquired":true,"shares":3704,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"On December 18, 2019, the issuer canceled, pursuant to the issuer's option exchange program, an option for 50,000 shares of the Issuer's common stock granted to the reporting person on March 31, 2017. In exchange, the reporting person received two replacement options, for an aggregate of 33,333 shares, having an exercise price of $2.45 a share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests as follows:  1/3rd shall vest on December 18, 2020, and the balance of the shares will vest in twenty-four (24) equal monthly installments thereafter, such that all shares subject to the option shall be fully vested on December 18, 2022."}],"balance_after":3704,"derivative":{"exercise_price":2.45,"expiration_date":"2026-12-17","underlying":"Common Stock","underlying_shares":3704},"source":{"system":"sec-edgar","filing":"0001209191-19-061574","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919119061574/doc4.xml","form_type":"4"}},{"id":3333728,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-12-20T16:36:48.000Z","date":"2019-12-18","kind":"grant","acquired":true,"shares":29629,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"On December 18, 2019, the issuer canceled, pursuant to the issuer's option exchange program, an option for 50,000 shares of the Issuer's common stock granted to the reporting person on March 31, 2017. In exchange, the reporting person received two replacement options, for an aggregate of 33,333 shares, having an exercise price of $2.45 a share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option shall vest in full on December 18, 2020."}],"balance_after":29629,"derivative":{"exercise_price":2.45,"expiration_date":"2026-12-17","underlying":"Common Stock","underlying_shares":29629},"source":{"system":"sec-edgar","filing":"0001209191-19-061574","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919119061574/doc4.xml","form_type":"4"}},{"id":3333727,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-12-20T16:36:48.000Z","date":"2019-12-18","kind":"disposition_to_issuer","acquired":false,"shares":50000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"On December 18, 2019, the issuer canceled, pursuant to the issuer's option exchange program, an option for 50,000 shares of the Issuer's common stock granted to the reporting person on March 31, 2017. In exchange, the reporting person received two replacement options, for an aggregate of 33,333 shares, having an exercise price of $2.45 a share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option provided for vesting in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 31, 2017 such that the option would have been fully vested on March 31, 2020."}],"balance_after":0,"derivative":{"exercise_price":7.8,"expiration_date":"2027-03-30","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-19-061574","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919119061574/doc4.xml","form_type":"4"}},{"id":3333726,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-12-20T16:36:48.000Z","date":"2019-12-18","kind":"grant","acquired":true,"shares":9721,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 18, 2019, the issuer canceled, pursuant to the issuer's option exchange program, an option for 100,000 shares of the Issuer's common stock granted to the reporting person on July 1, 2016. In exchange, the reporting person received two replacement options, for an aggregate of 66,666 shares, having an exercise price of $2.45 a share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option vests as follows:  1/3rd shall vest on December 18, 2020, and the balance of the shares will vest in twenty-four (24) equal monthly installments thereafter, such that all shares subject to the option shall be fully vested on December 18, 2022."}],"balance_after":9721,"derivative":{"exercise_price":2.45,"expiration_date":"2026-12-17","underlying":"Common Stock","underlying_shares":9721},"source":{"system":"sec-edgar","filing":"0001209191-19-061574","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919119061574/doc4.xml","form_type":"4"}},{"id":3333725,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-12-20T16:36:48.000Z","date":"2019-12-18","kind":"grant","acquired":true,"shares":56945,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 18, 2019, the issuer canceled, pursuant to the issuer's option exchange program, an option for 100,000 shares of the Issuer's common stock granted to the reporting person on July 1, 2016. In exchange, the reporting person received two replacement options, for an aggregate of 66,666 shares, having an exercise price of $2.45 a share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The option shall vest in full on December 18, 2020."}],"balance_after":56945,"derivative":{"exercise_price":2.45,"expiration_date":"2026-12-17","underlying":"Common Stock","underlying_shares":56945},"source":{"system":"sec-edgar","filing":"0001209191-19-061574","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919119061574/doc4.xml","form_type":"4"}},{"id":3333724,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-12-20T16:36:48.000Z","date":"2019-12-18","kind":"disposition_to_issuer","acquired":false,"shares":100000,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F2","text":"On December 18, 2019, the issuer canceled, pursuant to the issuer's option exchange program, an option for 100,000 shares of the Issuer's common stock granted to the reporting person on July 1, 2016. In exchange, the reporting person received two replacement options, for an aggregate of 66,666 shares, having an exercise price of $2.45 a share."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option provided for vesting as follows:  25% on July 1, 2017 with 1/36th of the remaining shares vesting monthly thereafter, such that all shares subject to the option would have been vested on July 1, 2020."}],"balance_after":0,"derivative":{"exercise_price":10.45,"expiration_date":"2026-06-30","underlying":"Common Stock","underlying_shares":100000},"source":{"system":"sec-edgar","filing":"0001209191-19-061574","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919119061574/doc4.xml","form_type":"4"}},{"id":3397947,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2019-10-03T21:13:17.000Z","date":"2019-10-01","kind":"sale","acquired":false,"shares":7284,"price":1.98,"value":14422.32,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of RSUs on 9/12/19. These sales are mandated by the Reporting Person's election to require the satisfaction of a tax withholding obligation to be funded by a \"sell to cover\" transaction and do not represent discretionary trades by the Reporting Person."}],"balance_after":49588,"source":{"system":"sec-edgar","filing":"0001209191-19-052479","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919119052479/doc4.xml","form_type":"4"}},{"id":3413502,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Unit","published_at":"2019-09-16T17:26:48.000Z","date":"2019-09-12","kind":"exercise","acquired":false,"shares":4900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"shares","element":"transactionShares","label":"F3","text":"This transaction relates to the vesting of shares upon the achievement of various clinical and corporate milestones that were previously reported in Table II of the Reporting Person's Form 4 filed 2/1/19."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"A portion of the shares vest upon the achievement of various clinical and corporate milestones."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"A portion of the shares vest upon the achievement of various clinical and corporate milestones."}],"balance_after":9100,"derivative":{"underlying":"Common Stock","underlying_shares":4900},"source":{"system":"sec-edgar","filing":"0001209191-19-049681","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919119049681/doc4.xml","form_type":"4"}},{"id":3413501,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Unit","published_at":"2019-09-16T17:26:48.000Z","date":"2019-09-12","kind":"exercise","acquired":false,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F4","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction relates to the vesting of shares upon the achievement of various clinical and corporate milestones that were previously reported in Table II of the Reporting Person's Form 4 filed 9/19/17."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"A portion of the shares vest upon the achievement of various clinical and corporate milestones."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F5","text":"A portion of the shares vest upon the achievement of various clinical and corporate milestones."}],"balance_after":7500,"derivative":{"underlying":"Common Stock","underlying_shares":17500},"source":{"system":"sec-edgar","filing":"0001209191-19-049681","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919119049681/doc4.xml","form_type":"4"}},{"id":3413500,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2019-09-16T17:26:48.000Z","date":"2019-09-12","kind":"grant","acquired":true,"shares":4900,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"This transaction relates to the vesting of shares upon the achievement of various clinical and corporate milestones that were previously reported in Table II of the Reporting Person's Form 4 filed 2/1/19."}],"balance_after":56872,"source":{"system":"sec-edgar","filing":"0001209191-19-049681","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919119049681/doc4.xml","form_type":"4"}},{"id":3413499,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2019-09-16T17:26:48.000Z","date":"2019-09-12","kind":"grant","acquired":true,"shares":17500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This transaction relates to the vesting of shares upon the achievement of various clinical and corporate milestones that were previously reported in Table II of the Reporting Person's Form 4 filed 9/19/17."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 4,000 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 20, 2019."}],"balance_after":51972,"source":{"system":"sec-edgar","filing":"0001209191-19-049681","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919119049681/doc4.xml","form_type":"4"}},{"id":3580661,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2019-03-22T16:40:08.000Z","date":"2019-03-21","kind":"grant","acquired":true,"shares":77000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 21, 2019."}],"balance_after":77000,"derivative":{"exercise_price":2.61,"expiration_date":"2029-03-20","underlying":"Common Stock","underlying_shares":77000},"source":{"system":"sec-edgar","filing":"0001209191-19-021005","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919119021005/doc4.xml","form_type":"4"}},{"id":3603659,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2019-03-08T19:30:34.000Z","date":"2019-03-08","kind":"sale","acquired":false,"shares":2300,"price":2.44,"value":5612.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The shares were sold to cover the tax obligation that occurred upon the vesting of restricted stock units."}],"balance_after":30472,"source":{"system":"sec-edgar","filing":"0001209191-19-018294","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919119018294/doc4.xml","form_type":"4"}},{"id":3679284,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Unit","published_at":"2019-02-01T19:08:16.000Z","date":"2019-01-31","kind":"exercise","acquired":true,"shares":14000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares shall vest upon the achievement of various clinical and corporate milestones."}],"balance_after":14000,"derivative":{"expiration_date":"2022-01-01","underlying":"Common Stock","underlying_shares":14000},"source":{"system":"sec-edgar","filing":"0001209191-19-006613","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919119006613/doc4.xml","form_type":"4"}},{"id":3679283,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2019-02-01T19:08:16.000Z","date":"2019-01-31","kind":"grant","acquired":true,"shares":6000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"1/3rd of the total number of shares subject to the restricted stock unit shall vest on each January 1 of 2020, 2021 and 2022."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,437, 2,109 and 2,805 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on November 20, 2017, May 18, 2018 and November 20 2018, respectively."}],"balance_after":32772,"source":{"system":"sec-edgar","filing":"0001209191-19-006613","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919119006613/doc4.xml","form_type":"4"}},{"id":3975955,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2018-04-02T17:20:37.000Z","date":"2018-03-29","kind":"grant","acquired":true,"shares":70000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 29, 2018."}],"balance_after":70000,"derivative":{"exercise_price":4,"expiration_date":"2028-03-28","underlying":"Common Stock","underlying_shares":70000},"source":{"system":"sec-edgar","filing":"0001209191-18-022512","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919118022512/doc4.xml","form_type":"4"}},{"id":4205359,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Restricted Stock Unit","published_at":"2017-09-19T16:58:00.000Z","date":"2017-09-18","kind":"exercise","acquired":true,"shares":25000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Restricted stock units convert into common stock on a one-for-one basis."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"A portion of the shares vest upon the achievement of various clinical and corporate milestones."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F4","text":"A portion of the shares vest upon the achievement of various clinical and corporate milestones."}],"balance_after":25000,"derivative":{"underlying":"Common Stock","underlying_shares":25000},"source":{"system":"sec-edgar","filing":"0001209191-17-053312","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919117053312/doc4.xml","form_type":"4"}},{"id":4205358,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Common Stock","published_at":"2017-09-19T16:58:00.000Z","date":"2017-09-18","kind":"grant","acquired":true,"shares":15000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"1/3rd of the total number of shares subject to the restricted stock unit shall vest on each December 31 of 2018, 2019 and 2020."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Includes 1,421 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan on May 19, 2017."}],"balance_after":20421,"source":{"system":"sec-edgar","filing":"0001209191-17-053312","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919117053312/doc4.xml","form_type":"4"}},{"id":4359767,"issuer":{"id":69639,"kind":"organization","name":"Cidara Therapeutics, Inc.","symbol":"CDTX"},"owners":[{"id":88177,"kind":"person","name":"Abdollahian Neil","position":1,"cik":"0001678223","reported_name":"Abdollahian Neil","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Business Officer"}}],"security":"Employee Stock Option (right to buy)","published_at":"2017-04-04T16:42:27.000Z","date":"2017-03-31","kind":"grant","acquired":true,"shares":50000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The option shall vest and become exercisable in a series of thirty-six (36) successive equal monthly installments measured from the Vesting Commencement Date of March 31, 2017."}],"balance_after":50000,"derivative":{"exercise_price":7.8,"expiration_date":"2027-03-30","underlying":"Common Stock","underlying_shares":50000},"source":{"system":"sec-edgar","filing":"0001209191-17-024876","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1610618/000120919117024876/doc4.xml","form_type":"4"}}]}